You are here

Generic Tiazac Approved for Hypertension

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--April 10, 2003--Andrx Corporation (Nasdaq:ADRX - News) today announced that the United States Food and Drug Administration (FDA) has approved the marketing of its Abbreviated New Drug Application (ANDA), for the 120 mg., 180 mg., 240 mg., 300 mg., and 360 mg. strengths of its Diltiazem Hydrochloride Extended-release Capsules that are bioequivalent to Tiazac®. To be marketed under the name Taztia(TM), this product is a calcium channel blocker indicated for the treatment of hypertension and chronic stable angina. Tiazac is manufactured by Biovail Corporation, marketed by Forest Laboratories, Inc., and had 2002 U.S. sales of $270 million.

Richard J. Lane, Andrx's Chief Executive Officer, remarked: "I am exceedingly pleased to announce this approval which we have anticipated receiving for a long time. Although we have maintained that our product was bioequivalent and stable, receiving final FDA approval ends all speculation. Simultaneous with this final marketing approval, we plan to launch all strengths of Taztia. We believe that Taztia will be a significant contributor to Andrx's 2003 operating results."

Though FDA awarded Andrx's ANDA a 180-day period of marketing exclusivity, that exclusivity period has expired.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs